Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Light beams to calm the brain: new trial tests stress relief for epilepsy

NCT ID NCT07509177

Symptom relief Sponsor: Cynthia Kerson Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether shining low-level infrared light on the scalp (photobiomodulation) can lower stress and improve seizure control in people with epilepsy. Eighty adults with epilepsy will attend 45 sessions over 15 weeks. Researchers will measure changes in perceived stress and seizure patterns.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
photobiomodulation (low-level light therapy)
What this could lead to
If it works, this could offer a non-invasive way to reduce stress and possibly seizure frequency in people with epilepsy.
What could go wrong
This is an early study with no control group, so results may be due to placebo. The effect on seizures is uncertain, and the time commitment is high.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • \>18 YO * Epilepsy - medical diagnosis with at least one seizure within the past 6 months: diagnosis to be obtained from medical records from the treating physician by signature of HIPAA-compliant medical release form * Agreement to maintain or reduce medication regimen (based upon prescribers' advice) * Available for intake, baseline, post-treatment, 6-month follow-up assessments, and 45 sessions of PBM * Willingness to wear an Õura ring at all times (except for charging) for the duration of the study. Exclusion: * \< 17 YO * Substance use * Personality disorders * Heavy metal toxicity * Mold toxicity * Metabolic measures thresholded based on participant type * Increase in current medication (dosage and/or type) * No new medications prescribed (reduction as prescribed by prescribing physician OK) * Current brain bleed * Acute TBI within the last 12 months * History of neuromodulation, including ECT * Brain implants/pumps/shunts * History of brain surgery * Hormone replacement therapy for menopause or gender transition * Untreated sleep disorders Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epilepsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epilepsy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Brain Health Center Miami

    RECRUITING

    North Miami, Florida, 33162, United States

  • Holly Maggiano, MD

    RECRUITING

    Warren, Ohio, 44484, United States

  • Houston Neuroscience Brain Center

    RECRUITING

    Houston, Texas, 77098, United States

  • Right Mind Wellness Center

    RECRUITING

    Cincinnati, Ohio, 45227, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.